# Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

> **NCT05823701** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 23 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Azacitidine
- **BIOLOGICAL:** obinutuzumab
- **DRUG:** Liposomal mitoxantrone

## Key facts

- **NCT ID:** NCT05823701
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823701, "Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05823701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*